Pfizer Aktie
25,76
EUR
+0,02
EUR
+0,06
%
26,80
USD
-0,11
USD
-0,39
%
Kursziele der Pfizer-Aktie in USD
Das durchschnittliche Kursziel beinhaltet alle Analysen eines Analysten und nicht nur die jeweils aktuellste Analyse, die im Chart dargestellt wird.
Diese Analysten bewerten die Pfizer-Aktie
| Analyst | Kursziel | Abstand Kursziel | Datum | |
|---|---|---|---|---|
| UBS AG | 31,00 USD | +15,74% | 19.12.2024 | |
| Jefferies & Company Inc. | 33,00 USD | +23,20% | 17.12.2024 | |
| JP Morgan Chase & Co. | 30,00 USD | +12,00% | 17.12.2024 | |
| Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | 29,00 USD | +8,27% | 29.11.2024 | |
| Goldman Sachs Group Inc. | 33,00 USD | +23,20% | 30.10.2024 | |
| DZ BANK | - | - | 31.07.2024 |
Werbung
Kursziele im Branchenvergleich
| Aktie | Buy | Hold | Sell | Ø Kursziel | Abst. Kursziel |
|---|---|---|---|---|---|
| Abbott Laboratories | 0 | 0 | 0 | - | - |
| Alexion Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Allergan Inc. | 0 | 0 | 0 | - | - |
| APONTIS PHARMA | 0 | 0 | 0 | - | - |
| AstraZeneca PLC | 5 | 4 | 0 | 134,95 GBP | +18,96% |
| Bayer | 1 | 8 | 0 | 24,12 EUR | +11,23% |
| Celgene Corp. | 0 | 0 | 0 | - | - |
| EVOTEC SE | 2 | 2 | 1 | 9,68 EUR | +11,33% |
| Gilead Sciences Inc. | 0 | 0 | 0 | - | - |
| GSK PLC Registered Shs | 2 | 6 | 1 | 16,49 GBP | +17,37% |
| Johnson & Johnson | 0 | 0 | 0 | - | - |
| Merck Co. | 0 | 0 | 0 | - | - |
| Merck KGaA | 7 | 1 | 0 | 184,00 EUR | +25,04% |
| MorphoSys | 1 | 2 | 0 | 41,33 EUR | - |
| Mylan N.V. | 0 | 0 | 0 | - | - |
| Novartis AG | 3 | 5 | 1 | 99,00 CHF | +3,58% |
| Perrigo Company | 0 | 0 | 0 | - | - |
| Pfizer Inc. | 3 | 3 | 0 | 31,20 USD | +16,48% |
| Roche Holding AG (Inhaberaktie) | 0 | 0 | 0 | - | - |
| Sanofi S.A. | 5 | 2 | 1 | 110,57 EUR | +5,83% |
| STADA | 0 | 0 | 0 | - | - |
| Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 0 | 0 | 0 | - | - |
| Vertex Pharmaceuticals Inc. | 0 | 0 | 0 | - | - |
| Warner Chilcott plc | 0 | 0 | 0 | - | - |